Karyopharm Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M |
| Selling, general & administrative | $105.2M | $115.4M | $131.9M | $145.4M | $143.8M |
| Research and development | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M |
| Operating expenses | $236.8M | $264.7M | $275.6M | $299.3M | $308.1M |
| Operating income | -$90.7M | -$119.4M | -$129.5M | -$142.2M | -$98.3M |
| Interest expense | $45.8M | $37.4M | $23.8M | $25.0M | $26.0M |
| Pretax income | -$196.0M | -$76.4M | -$142.8M | -$164.9M | -$123.8M |
| Income tax expense | $43,000 | $57,000 | $323,000 | $369,000 | $268,000 |
| Net income | -$196.0M | -$76.4M | -$143.1M | -$165.3M | -$124.1M |
| Balance Sheet | |||||
| Cash and equivalents | $60.5M | $62.5M | $52.2M | $135.2M | $190.5M |
| Current assets | $103.1M | $156.5M | $233.9M | $350.2M | $275.6M |
| Total assets | $108.4M | $164.4M | $240.4M | $358.2M | $305.3M |
| Current liabilities | $92.1M | $92.3M | $69.5M | $65.9M | $73.7M |
| Total liabilities | $401.3M | $350.4M | $376.6M | $374.8M | $385.0M |
| Total debt | — | — | — | — | $193.2M |
| Stockholders' equity | -$292.9M | -$186.0M | -$136.2M | -$16.7M | -$79.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$75.4M | -$127.5M | -$92.7M | -$149.6M | -$107.1M |
| Depreciation and amortization | $296,000 | $340,000 | $530,000 | $621,000 | $789,000 |
| Stock-based compensation | $14.1M | $18.4M | $21.7M | $35.4M | $29.8M |
| Capital expenditure | $0 | $142,000 | $0 | $118,000 | $212,000 |
| Free cash flow | -$75.4M | -$127.6M | -$92.7M | -$149.7M | -$107.3M |
Shares outstanding 22.7M · Free float 65.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.